Patients with age-related macular degeneration may soon see their monthly injection become an annual refill, with potentially better results
A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments. This represents a vast improvement over the typical regimen of nearly monthly eye injections. The researchers involved in the Phase II clinical study say the implant is not just about convenience; a more consistent treatment will also help people keep more of their vision. They are presenting their research today at AAO 2018, the 122nd Annual Meeting of the American Academy of Ophthalmology.
A lead researcher from Wills Eye Hospital in Philadelphia is presenting results from the LADDER study evaluating the efficacy and safety of an investigational, long-acting port delivery system for Lucentis (ranibizumab), a drug that improves vision for millions across the globe suffering from age-related macular degeneration.
The multicenter, randomized trial included 220 patients. The study determined the time until a patient needed a refill of the implant. It also evaluated the effectiveness of three different concentrations of Lucentis compared with monthly injections of the drug.
Before Lucentis was introduced 12 years ago, people with wet AMD were almost certain to develop severe vision loss or blindness. Lucentis was the first treatment to slow the disease, allowing more than 90 percent of patients to keep their vision, according to clinical trials. However, in the real world, the percentage is closer to 50 percent. One of the main reasons why is that patients are undertreated. This is because most people with AMD must go to the ophthalmologist’s office every six to eight weeks to keep their vision. This can be a difficult schedule to maintain for many elderly patients struggling with other maladies and reliant on others to get them to their ophthalmologist visits.
Researchers have been searching for a better alternative to monthly injections almost from the moment Lucentis was introduced. One of the latest ideas is to surgically implant a refillable drug reservoir device, slightly longer than a grain of rice, into the eye. Filled with a concentrated version of Lucentis, the device, called the port delivery system, delivers drug to the back of the eye over a longer time frame.
Lead site investigator, Carl D. Regillo, M.D., chief of retina service and professor of Ophthalmology at Wills Eye Hospital, said that patients treated with the highest drug concentration were able to go a median of 15 months before needing a refill. Port delivery treatment was also as effective as monthly injections.
“Fewer injections and office visits is exciting,” said Dr. Regillo, who administers more than 100 injections a week. “But more importantly, we think it will translate into better visual outcomes because in the real world, patients get less treatment than they need. It’s not done consciously. Over time, things happen: illness, hospitalization, a snowstorm, etc. and appointments are missed or delayed. If you’re a week or two late for a visit from time to time, you may have a decline in vision, and you can’t always recover from that. It’s a relentlessly progressive disease.”
The study did find some side effects from surgery, but the overall safety profile was good. The device is not visible on the outside of the eye. It’s implanted under the eyelid, appearing, at most, as a tiny dot. After the initial surgery, it can be refilled during an office visit.
Dr. Regillo anticipates that the new delivery system could be available to patients in about three years.
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- A device for the early detection of certain eyesight problemson March 27, 2020 at 6:45 am
The technology could be extremely useful for ophthalmologists, in particular for detecting age-related macular degeneration early and assessing new treatment options. The retina is a complex tissue ...
- Emerging Drug Delivery Systems for Posterior Segment Diseaseon March 26, 2020 at 5:56 pm
The use of intravitreal injection therapy for age-related macular degeneration, retinal vascular disease, and uveitis has revolutionized our ability to effectively treat a myriad of posterior segment ...
- Genentech Says It Shouldn't Lose Patent Rights Over Erroron March 26, 2020 at 4:19 pm
The biotechnology company is fighting to extend what's known as a supplementary protection certificate, or SPC, for an antibody marketed under the brand name Lucentis used to treat an eye disorder ...
- Bayer And Novartis Lose Challenge To NHS Eye Drug Policyon March 25, 2020 at 3:20 pm
There is widespread use of Avastin to treat wet age-related macular degeneration in the United States, developing countries and to some extent in Europe, the appellate court noted in its Wednesday ...
- seeBOOST Electronic Glasses Improve Central Vision: Interview with CEO Patrick Antakion March 25, 2020 at 2:12 pm
Our founders recognized that by applying their skills and knowledge they could create a lightweight, head-mounted system that could be used for extended periods of time and offer improved quality of ...
- Coronavirus and eye disease: What older people should knowon March 24, 2020 at 3:17 am
At the American Macular Degeneration Foundation (AMDF) we have been thinking a lot about how many of you in the age-related macular degeneration (AMD) community may be concerned about being more ...
- A tooth-enamel protein is found in eyes with a common form of macular degenerationon March 23, 2020 at 5:05 am
Deposits of a mineral found in tooth enamel at the back of the eye could be hastening the progression of age-related macular degeneration, the leading cause of deteriorating eyesight in people over 50 ...
- Enrollment complete in Graybug’s phase 2b wet AMD treatment trialon March 20, 2020 at 11:17 am
The final patient has been enrolled in a phase 2b trial of Graybug Vision’s wet age-related macular degeneration treatment candidate, according to a press release. The multicenter, prospective, masked ...
- RIBOMIC Enters License Agreement with AJU Pharma for RBM-007 in Age-related Macular Degenerationon March 17, 2020 at 5:05 pm
RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company for RBM-007 licensing agreement.
via Bing News